Pluristem Therapeutics (NASDAQ:PSTI) Lifted to Hold at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Pluristem Therapeutics (NASDAQ:PSTI) from a sell rating to a hold rating in a research note issued to investors on Wednesday, Zacks.com reports.

According to Zacks, “PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells. “

Separately, Maxim Group restated a buy rating and issued a $315.00 target price (up previously from $305.00) on shares of Domino’s Pizza in a research note on Wednesday, April 24th.

PSTI opened at $0.56 on Wednesday. The company has a 50 day moving average price of $0.60. Pluristem Therapeutics has a 52 week low of $0.50 and a 52 week high of $1.38.

Pluristem Therapeutics (NASDAQ:PSTI) last released its earnings results on Monday, May 6th. The biotechnology company reported ($0.09) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.02). As a group, analysts expect that Pluristem Therapeutics will post -0.31 earnings per share for the current year.

Large investors have recently made changes to their positions in the business. Van ECK Associates Corp grew its holdings in shares of Pluristem Therapeutics by 38.7% in the fourth quarter. Van ECK Associates Corp now owns 50,443 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 14,087 shares during the period. Virtu Financial LLC grew its holdings in Pluristem Therapeutics by 266.1% during the first quarter. Virtu Financial LLC now owns 85,104 shares of the biotechnology company’s stock valued at $83,000 after purchasing an additional 61,858 shares during the period. Sumitomo Mitsui Trust Holdings Inc. bought a new stake in Pluristem Therapeutics during the first quarter valued at about $881,000. Nikko Asset Management Americas Inc. bought a new stake in Pluristem Therapeutics during the first quarter valued at about $900,000. Finally, ARK Investment Management LLC grew its holdings in Pluristem Therapeutics by 12.0% during the first quarter. ARK Investment Management LLC now owns 3,793,249 shares of the biotechnology company’s stock valued at $3,679,000 after purchasing an additional 406,155 shares during the period. Institutional investors and hedge funds own 6.00% of the company’s stock.

About Pluristem Therapeutics

Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

Read More: Is it better to buy a fund with a higher or lower NAV?

Get a free copy of the Zacks research report on Pluristem Therapeutics (PSTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.